Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Clin Infect Dis. 2023 Jul 5;77(1):138-144. doi: 10.1093/cid/ciad132.
The World Health Organization recommends vaccines for prevention and control of typhoid fever, especially where antimicrobial-resistant typhoid circulates. In 2018, the Navi Mumbai Municipal Corporation (NMMC) implemented a typhoid conjugate vaccine (TCV) campaign. The campaign targeted all children aged 9 months through 14 years within NMMC boundaries (approximately 320 000 children) over 2 vaccination phases. The phase 1 campaign occurred from 14 July 2018 through 25 August 2018 (71% coverage, approximately 113 420 children). We evaluated the phase 1 campaign's programmatic effectiveness in reducing typhoid cases at the community level.
We established prospective, blood culture-based surveillance at 6 hospitals in Navi Mumbai and offered blood cultures to children who presented with fever ≥3 days. We used a cluster-randomized (by administrative boundary) test-negative design to estimate the effectiveness of the vaccination campaign on pediatric typhoid cases. We matched test-positive, culture-confirmed typhoid cases with up to 3 test-negative, culture-negative controls by age and date of blood culture and assessed community vaccine campaign phase as an exposure using conditional logistic regression.
Between 1 September 2018 and 31 March 2021, we identified 81 typhoid cases and matched these with 238 controls. Cases were 0.44 times as likely to live in vaccine campaign communities (programmatic effectiveness, 56%; 95% confidence interval [CI], 25% to 74%; P = .002). Cases aged ≥5 years were 0.37 times as likely (95% CI, .19 to .70; P = .002) and cases during the first year of surveillance were 0.30 times as likely (95% CI, .14 to .64; P = .002) to live in vaccine campaign communities.
Our findings support the use of TCV mass vaccination campaigns as effective population-based tools to combat typhoid fever.
世界卫生组织建议使用疫苗来预防和控制伤寒,特别是在出现耐药性伤寒的地方。2018 年,那瓦西 Municipal Corporation(NMMC)实施了伤寒结合疫苗(TCV)运动。该运动针对 NMMC 范围内的所有 9 个月至 14 岁儿童(约 32 万名儿童),分两个阶段进行疫苗接种。第一阶段运动于 2018 年 7 月 14 日至 8 月 25 日进行(覆盖率为 71%,约 113420 名儿童)。我们评估了第一阶段运动在社区层面降低伤寒病例的计划有效性。
我们在那瓦西的 6 家医院建立了前瞻性、基于血液培养的监测,并为发热≥3 天的儿童提供血液培养。我们使用集群随机(按行政边界)的测试阴性设计来估计疫苗接种运动对儿科伤寒病例的效果。我们通过年龄和血液培养日期将测试阳性、培养阳性的伤寒病例与最多 3 名测试阴性、培养阴性的对照进行匹配,并使用条件逻辑回归评估社区疫苗接种阶段作为暴露因素。
在 2018 年 9 月 1 日至 2021 年 3 月 31 日期间,我们确定了 81 例伤寒病例,并将这些病例与 238 名对照进行了匹配。病例组居住在疫苗接种社区的可能性低 44%(计划有效性为 56%;95%置信区间[CI],25%至 74%;P=0.002)。年龄≥5 岁的病例低 37%(95%CI,.19 至.70;P=0.002),监测第一年的病例低 30%(95%CI,.14 至.64;P=0.002)。
我们的研究结果支持使用 TCV 大规模疫苗接种运动作为防治伤寒的有效人群工具。